The company's lead product candidate is Silenor, a low-dose oral tablet formulation of doxepin for the treatment of insomnia. Silenor selectively blocks histamine at the H1 receptor without causing side effects associated with higher doses of doxepin. Somaxon Pharmaceuticals aims to address unmet medical needs and patient dissatisfaction by in-licensing, developing, and marketing proprietary products in the neuropsychiatry field. Currently, the company is promoting Silenor as the first nonscheduled prescription medication approved for sleep maintenance insomnia in the United States.